People · Operator
Named in public records as an officer, director or promoter · active 2017–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NextCure, Inc. | — | Biotechnology | Series C | $129.9M | $113.9M | 2025 |
| Antiva Biosciences, Inc. | — | Biotechnology | Series B | $96.8M | $457.8M | 2017 |
David P. Kabakoff at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David P. Kabakoff on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Kabakoff | 2 | 7 |
| Wende Hutton | 1 | 16 |
| Judith Li | 1 | 8 |
| Michael Cannon | 1 | 4 |
| Vinzenz Ploerer | 1 | 4 |
| Michael Yi | 1 | 4 |
| Michael J Sullivan | 1 | 4 |
| Steven James | 1 | 3 |
| ASHER RUBIN | 1 | 3 |
| Elaine V. Jones | 1 | 3 |
| Steven P. James | 1 | 3 |
| Jenny Yip | 1 | 3 |
| Benjamin Rovinski | 1 | 3 |
| John G. Houston | 1 | 2 |
| John W. Sayward | 1 | 2 |
| MICHAEL RICHMAN | 1 | 2 |
| Wende S. Hutton | 1 | 2 |
| Michael D. Cannon | 1 | 2 |
| CAROLYN GREEN | 1 | 2 |
| Vinzenz P. Ploerer | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.